Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05254834
Other study ID # The Vallania Study/FRNM-008
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 15, 2022
Est. completion date June 30, 2025

Study information

Verified date April 2024
Source Freenome Holdings Inc.
Contact Kavita Ramroop
Phone (650) 446-6630
Email frnm008@freenome.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This protocol is a case-control, multicenter, diagnostic study to collect blood samples to support the development of blood-based screening tests for multiple cancers.


Recruitment information / eligibility

Status Recruiting
Enrollment 5400
Est. completion date June 30, 2025
Est. primary completion date June 28, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 30 Years and older
Eligibility Key Inclusion Criteria: - Age at least 30 years - Able and willing to provide blood samples per protocol - Able to comprehend and willing to sign and date the informed consent documents - Participants must meet one of the following: - Diagnosed with a single primary cancer that has not yet been treated - No evidence or treatment of any cancer for at least 5 years prior to enrollment Key Exclusion Criteria: - A medical condition which, in the opinion of the investigator, should preclude enrollment in the study - Known to be pregnant - Any therapy for cancer, including surgery, chemotherapy, immunotherapy, and/or radiation therapy in the 5 years preceding enrollment - Participated or currently participating in a clinical research study in which an experimental medication has been administered in the last 30 days - Participated in or currently participating in another Freenome clinical study - For the control cohort: Any previous cancer diagnosis in the 5 years preceding enrollment, or recurrence of the same primary cancer within any timeframe; or concurrent diagnosis of multiple primary cancers within any timeframe - For the cancer cohorts: Any previous cancer diagnosis in the 5 years preceding enrollment, apart from the current cancer diagnosis; OR recurrence of the same primary cancer within any timeframe; OR concurrent diagnosis of multiple primary cancers within any timeframe

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Freenome Test
Participants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled.

Locations

Country Name City State
United States University of Michigan Ann Arbor Michigan
United States Morehouse School of Medicine Atlanta Georgia
United States Mercy Medical Center Baltimore Maryland
United States St. Charles Health System, Inc Bend Oregon
United States Billings Clinic Billings Montana
United States Alabama Oncology Birmingham Alabama
United States Central Alabama Research Birmingham Alabama
United States Central Care Cancer Center Bolivar Missouri
United States Massachusetts General Hospital Boston Massachusetts
United States RecioMed Clinical Research Boynton Beach Florida
United States Gabrail Cancer Center Research Canton Ohio
United States University of Chicago Chicago Illinois
United States John Muir Health Concord California
United States Carbon Health Corona California
United States Christus Spohn Shoreline Hospital Corpus Christi Texas
United States Objective Health Network Dayton Ohio
United States Doylestown Health Doylestown Pennsylvania
United States Cancer Center of Middle Georgia (QCCA) Dublin Georgia
United States Miller Bioconnect El Cajon California
United States Gastroenterology and Liver Institute Escondido California
United States ObjectiveHealth, Inc Franklin Tennessee
United States Women's Cancer Network Fresno California
United States Specicare Gainesville Georgia
United States Pennsylvania Cancer Specialists & Research Institute Gettysburg Pennsylvania
United States Altru Health System Grand Forks North Dakota
United States Oncology Consultants Houston Texas
United States The University of Texas M.D. Anderson Cancer Center Houston Texas
United States Logan Health Research Kalispell Montana
United States San Diego Clinical Trials La Mesa California
United States Saint Joseph Cancer Center Lexington Kentucky
United States Urology Alliance Clinical Research Los Angeles California
United States Centra Lynchburg Hematology Oncology Lynchburg Virginia
United States SSM Health-Dean Medical Group Madison Wisconsin
United States Mercy UC Davis Cancer Center (CommonSpirit) Merced California
United States University of Minnesota, School of Public Health, Environmental Health Sciences Minneapolis Minnesota
United States NYU New York New York
United States Eastern CT Hematology and Oncology Associates Norwich Connecticut
United States Hightower Clinical Research Oklahoma City Oklahoma
United States Mid Florida Hematology & Oncology Center Orange City Florida
United States Emerald Coast OBGYN Panama City Florida
United States Ascension Sacred Heart Pensacola Florida
United States Thomas Jefferson University Philadelphia Pennsylvania
United States Pomona Valley Hospital Medical Center/Cancer Care Center Pomona California
United States NY Cancer & Blood Specialists Port Jefferson Station New York
United States Cancer Care Specialists Reno Reno Nevada
United States Objective Health Network Richmond Virginia
United States Ascension Providence Rochester Hospital Rochester Hills Michigan
United States Carolina Blood and Cancer Care Associates Rock Hill South Carolina
United States Northwest Oncology & Hematology Rolling Meadows Illinois
United States Covenant HealthCare Saginaw Michigan
United States St. Mary's Medical Center San Francisco California
United States Dominican Hospital Dignity Health Santa Cruz California
United States Donald Guthrie Foundation Sayre Pennsylvania
United States Honor Health Scottsdale Arizona
United States Louisiana Research Center, LLC Shreveport Louisiana
United States Louisiana State University Health Sciences Center Shreveport Louisiana
United States Avera Cancer Institute Sioux Falls South Dakota
United States Highlands Oncology Group Springdale Arkansas
United States Stockton Hematology Oncology Stockton California
United States Northwest Medical Specialties (QCCA) Tacoma Washington
United States Torrance Memorial Physician Network - Cancer Care Torrance California
United States Christus Trinity Mother Frances Health System Tyler Texas
United States Inspira Medical Center Vineland Vineland New Jersey
United States White Plains Hospital White Plains New York
United States Ascension Via Christi Hospital, Wichita Wichita Kansas
United States USDH Clinical Research Wyomissing Pennsylvania
United States Cancer Care Associates of York (QCCA) York Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Freenome Holdings Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison of Blood Samples from Cancer Case and Non-cancer Control Participants To compare blood samples from cancer case and non-cancer control subjects in order to develop and characterize blood-based multiomics tests in specific cancer types or in a combination of multiple cancers. 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients